nodes	percent_of_prediction	percent_of_DWPC	metapath
Nafarelin—Pentagastrin—CCKBR—pancreatic cancer	0.0189	0.436	CrCbGaD
Nafarelin—Ceruletide—CCKAR—pancreatic cancer	0.0161	0.371	CrCbGaD
Nafarelin—GNRHR—Peptide GPCRs—SSTR3—pancreatic cancer	0.0125	0.0426	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—SSTR1—pancreatic cancer	0.012	0.0408	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—SSTR2—pancreatic cancer	0.0115	0.0393	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—CCKBR—pancreatic cancer	0.0111	0.0379	CbGpPWpGaD
Nafarelin—GNRHR—GPCRs, Other—SSTR2—pancreatic cancer	0.00976	0.0333	CbGpPWpGaD
Nafarelin—GNRHR—GPCRs, Other—CCKBR—pancreatic cancer	0.00942	0.0321	CbGpPWpGaD
Nafarelin—GNRHR—Peptide GPCRs—CCKAR—pancreatic cancer	0.00829	0.0283	CbGpPWpGaD
Nafarelin—Vapreotide—SSTR2—pancreatic cancer	0.00785	0.181	CrCbGaD
Nafarelin—GNRHR—Peptide GPCRs—AGTR1—pancreatic cancer	0.00557	0.019	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—CCKBR—pancreatic cancer	0.0053	0.0181	CbGpPWpGaD
Nafarelin—GNRHR—GPCRs, Other—CNR1—pancreatic cancer	0.00513	0.0175	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CCKBR—pancreatic cancer	0.00474	0.0162	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—PRLHR—pancreatic cancer	0.00463	0.0158	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—GAST—pancreatic cancer	0.00455	0.0155	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—CCK—pancreatic cancer	0.00412	0.0141	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GAST—pancreatic cancer	0.00407	0.0139	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—CCKAR—pancreatic cancer	0.00395	0.0135	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—SSTR3—pancreatic cancer	0.00394	0.0134	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—SSTR1—pancreatic cancer	0.00377	0.0129	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—PPY—pancreatic cancer	0.0037	0.0126	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CCK—pancreatic cancer	0.00368	0.0126	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—SSTR2—pancreatic cancer	0.00363	0.0124	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—CCKAR—pancreatic cancer	0.00353	0.012	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—PRLHR—pancreatic cancer	0.00352	0.012	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCKBR—pancreatic cancer	0.00351	0.012	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—SSTR3—pancreatic cancer	0.003	0.0102	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—SSTR1—pancreatic cancer	0.00287	0.0098	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—PPY—pancreatic cancer	0.00282	0.00961	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—GCG—pancreatic cancer	0.00278	0.00949	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—SSTR2—pancreatic cancer	0.00277	0.00944	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCK—pancreatic cancer	0.00273	0.00931	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCKBR—pancreatic cancer	0.00267	0.00911	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR2—pancreatic cancer	0.00266	0.00907	CbGpPWpGaD
Nafarelin—GNRHR—G alpha (q) signalling events—AGTR1—pancreatic cancer	0.00265	0.00905	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CCKAR—pancreatic cancer	0.00262	0.00892	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—GCG—pancreatic cancer	0.00249	0.00849	CbGpPWpGaD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—AGTR1—pancreatic cancer	0.00237	0.0081	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—SCT—pancreatic cancer	0.00218	0.00743	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCK—pancreatic cancer	0.00208	0.00709	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—SST—pancreatic cancer	0.00207	0.00705	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CNR2—pancreatic cancer	0.00202	0.00691	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—GLP1R—pancreatic cancer	0.00202	0.00691	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CCKAR—pancreatic cancer	0.00199	0.00679	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CNR1—pancreatic cancer	0.00191	0.00651	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—SHH—pancreatic cancer	0.00182	0.00619	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PRLHR—pancreatic cancer	0.00181	0.00617	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—IAPP—pancreatic cancer	0.00179	0.00612	CbGpPWpGaD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—AGTR1—pancreatic cancer	0.00176	0.006	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—PTHLH—pancreatic cancer	0.00172	0.00587	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—PTCH1—pancreatic cancer	0.00172	0.00587	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—SSTR3—pancreatic cancer	0.00169	0.00578	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GDI1—pancreatic cancer	0.00166	0.00566	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—GDI2—pancreatic cancer	0.00166	0.00566	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—SSTR1—pancreatic cancer	0.00162	0.00554	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PPY—pancreatic cancer	0.00159	0.00543	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—SST—pancreatic cancer	0.00157	0.00537	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—SSTR2—pancreatic cancer	0.00156	0.00533	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—SSTR3—pancreatic cancer	0.00154	0.00525	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CCKBR—pancreatic cancer	0.00151	0.00515	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—SSTR1—pancreatic cancer	0.00147	0.00503	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—CNR1—pancreatic cancer	0.00145	0.00496	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PPY—pancreatic cancer	0.00145	0.00493	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—SSTR2—pancreatic cancer	0.00142	0.00484	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—GCG—pancreatic cancer	0.0014	0.00479	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CCKBR—pancreatic cancer	0.00137	0.00468	CbGpPWpGaD
Nafarelin—GNRHR—GPCR ligand binding—AGTR1—pancreatic cancer	0.00134	0.00457	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GAST—pancreatic cancer	0.0013	0.00443	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—SCT—pancreatic cancer	0.00123	0.0042	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GAST—pancreatic cancer	0.00118	0.00402	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CCK—pancreatic cancer	0.00117	0.004	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—GLP1R—pancreatic cancer	0.00114	0.0039	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—CNR2—pancreatic cancer	0.00114	0.0039	CbGpPWpGaD
Nafarelin—Dyspnoea—Tamoxifen—pancreatic cancer	0.00113	0.00171	CcSEcCtD
Nafarelin—Cystitis—Epirubicin—pancreatic cancer	0.00113	0.00171	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CCKAR—pancreatic cancer	0.00113	0.00384	CbGpPWpGaD
Nafarelin—Dyspnoea—Erlotinib—pancreatic cancer	0.00112	0.00169	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—SCT—pancreatic cancer	0.00112	0.00381	CbGpPWpGaD
Nafarelin—Alopecia—Irinotecan—pancreatic cancer	0.00112	0.00168	CcSEcCtD
Nafarelin—Decreased appetite—Tamoxifen—pancreatic cancer	0.0011	0.00167	CcSEcCtD
Nafarelin—Coordination abnormal—Doxorubicin—pancreatic cancer	0.0011	0.00166	CcSEcCtD
Nafarelin—Decreased appetite—Erlotinib—pancreatic cancer	0.00109	0.00165	CcSEcCtD
Nafarelin—Oedema—Sunitinib—pancreatic cancer	0.00109	0.00164	CcSEcCtD
Nafarelin—Constipation—Tamoxifen—pancreatic cancer	0.00109	0.00164	CcSEcCtD
Nafarelin—Alopecia—Gemcitabine—pancreatic cancer	0.00109	0.00164	CcSEcCtD
Nafarelin—Pulmonary embolism—Doxorubicin—pancreatic cancer	0.00108	0.00163	CcSEcCtD
Nafarelin—Constipation—Erlotinib—pancreatic cancer	0.00108	0.00162	CcSEcCtD
Nafarelin—Shock—Sunitinib—pancreatic cancer	0.00107	0.00161	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PRLHR—pancreatic cancer	0.00107	0.00365	CbGpPWpGaD
Nafarelin—Alopecia—Fluorouracil—pancreatic cancer	0.00107	0.00161	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CCK—pancreatic cancer	0.00107	0.00364	CbGpPWpGaD
Nafarelin—Rash maculo-papular—Epirubicin—pancreatic cancer	0.00107	0.00161	CcSEcCtD
Nafarelin—Bladder pain—Epirubicin—pancreatic cancer	0.00106	0.0016	CcSEcCtD
Nafarelin—Neoplasm—Epirubicin—pancreatic cancer	0.00106	0.0016	CcSEcCtD
Nafarelin—Cystitis noninfective—Doxorubicin—pancreatic cancer	0.00106	0.0016	CcSEcCtD
Nafarelin—Cystitis—Doxorubicin—pancreatic cancer	0.00105	0.00158	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CNR2—pancreatic cancer	0.00104	0.00354	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—GLP1R—pancreatic cancer	0.00104	0.00354	CbGpPWpGaD
Nafarelin—Anorexia—Sunitinib—pancreatic cancer	0.00104	0.00156	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CCKAR—pancreatic cancer	0.00102	0.00349	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—IAPP—pancreatic cancer	0.00101	0.00346	CbGpPWpGaD
Nafarelin—Urticaria—Tamoxifen—pancreatic cancer	0.00101	0.00152	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—ACVR1B—pancreatic cancer	0.001	0.00343	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—ZNRF3—pancreatic cancer	0.001	0.00343	CbGpPWpGaD
Nafarelin—Weight increased—Docetaxel—pancreatic cancer	0.000992	0.0015	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Sunitinib—pancreatic cancer	0.000992	0.00149	CcSEcCtD
Nafarelin—Vertigo—Irinotecan—pancreatic cancer	0.000987	0.00149	CcSEcCtD
Nafarelin—Weight decreased—Docetaxel—pancreatic cancer	0.000986	0.00149	CcSEcCtD
Nafarelin—Rash maculo-papular—Doxorubicin—pancreatic cancer	0.000986	0.00149	CcSEcCtD
Nafarelin—Insomnia—Sunitinib—pancreatic cancer	0.000985	0.00148	CcSEcCtD
Nafarelin—Bladder pain—Doxorubicin—pancreatic cancer	0.00098	0.00148	CcSEcCtD
Nafarelin—Neoplasm—Doxorubicin—pancreatic cancer	0.00098	0.00148	CcSEcCtD
Nafarelin—Paraesthesia—Sunitinib—pancreatic cancer	0.000978	0.00147	CcSEcCtD
Nafarelin—Hepatic function abnormal—Epirubicin—pancreatic cancer	0.000973	0.00147	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PTHLH—pancreatic cancer	0.000973	0.00332	CbGpPWpGaD
Nafarelin—Dyspnoea—Sunitinib—pancreatic cancer	0.000971	0.00146	CcSEcCtD
Nafarelin—Acute coronary syndrome—Docetaxel—pancreatic cancer	0.000958	0.00144	CcSEcCtD
Nafarelin—Myocardial infarction—Docetaxel—pancreatic cancer	0.000953	0.00144	CcSEcCtD
Nafarelin—Decreased appetite—Sunitinib—pancreatic cancer	0.000946	0.00143	CcSEcCtD
Nafarelin—Conjunctivitis—Docetaxel—pancreatic cancer	0.000945	0.00142	CcSEcCtD
Nafarelin—Eye pain—Epirubicin—pancreatic cancer	0.000942	0.00142	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—SHH—pancreatic cancer	0.000932	0.00318	CbGpPWpGaD
Nafarelin—Constipation—Sunitinib—pancreatic cancer	0.000931	0.0014	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—IAPP—pancreatic cancer	0.00092	0.00314	CbGpPWpGaD
Nafarelin—Epistaxis—Docetaxel—pancreatic cancer	0.000917	0.00138	CcSEcCtD
Nafarelin—Asthenia—Tamoxifen—pancreatic cancer	0.000912	0.00137	CcSEcCtD
Nafarelin—Convulsion—Fluorouracil—pancreatic cancer	0.000912	0.00137	CcSEcCtD
Nafarelin—Myalgia—Gemcitabine—pancreatic cancer	0.000911	0.00137	CcSEcCtD
Nafarelin—Arthralgia—Gemcitabine—pancreatic cancer	0.000911	0.00137	CcSEcCtD
Nafarelin—Chest pain—Gemcitabine—pancreatic cancer	0.000911	0.00137	CcSEcCtD
Nafarelin—Hot flush—Epirubicin—pancreatic cancer	0.000909	0.00137	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—SSTR3—pancreatic cancer	0.000908	0.0031	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—DTX1—pancreatic cancer	0.000908	0.0031	CbGpPWpGaD
Nafarelin—Increased appetite—Epirubicin—pancreatic cancer	0.000905	0.00136	CcSEcCtD
Nafarelin—Asthenia—Erlotinib—pancreatic cancer	0.000902	0.00136	CcSEcCtD
Nafarelin—Menopausal symptoms—Epirubicin—pancreatic cancer	0.000902	0.00136	CcSEcCtD
Nafarelin—Hepatic function abnormal—Doxorubicin—pancreatic cancer	0.000901	0.00136	CcSEcCtD
Nafarelin—Pruritus—Tamoxifen—pancreatic cancer	0.000899	0.00136	CcSEcCtD
Nafarelin—Oedema—Irinotecan—pancreatic cancer	0.000897	0.00135	CcSEcCtD
Nafarelin—Myalgia—Fluorouracil—pancreatic cancer	0.000896	0.00135	CcSEcCtD
Nafarelin—Chest pain—Fluorouracil—pancreatic cancer	0.000896	0.00135	CcSEcCtD
Nafarelin—Pruritus—Erlotinib—pancreatic cancer	0.00089	0.00134	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—SST—pancreatic cancer	0.00089	0.00304	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PTHLH—pancreatic cancer	0.000883	0.00301	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PTCH1—pancreatic cancer	0.000883	0.00301	CbGpPWpGaD
Nafarelin—Shock—Irinotecan—pancreatic cancer	0.000882	0.00133	CcSEcCtD
Nafarelin—Rhinitis—Docetaxel—pancreatic cancer	0.000875	0.00132	CcSEcCtD
Nafarelin—Oedema—Gemcitabine—pancreatic cancer	0.000874	0.00132	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—pancreatic cancer	0.000873	0.00298	CbGpPWpGaD
Nafarelin—Eye pain—Doxorubicin—pancreatic cancer	0.000872	0.00131	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—SSTR1—pancreatic cancer	0.000871	0.00297	CbGpPWpGaD
Nafarelin—Diarrhoea—Tamoxifen—pancreatic cancer	0.00087	0.00131	CcSEcCtD
Nafarelin—Cerebrovascular accident—Epirubicin—pancreatic cancer	0.000868	0.00131	CcSEcCtD
Nafarelin—Hyperhidrosis—Irinotecan—pancreatic cancer	0.000867	0.00131	CcSEcCtD
Nafarelin—Diarrhoea—Erlotinib—pancreatic cancer	0.00086	0.0013	CcSEcCtD
Nafarelin—Oedema—Fluorouracil—pancreatic cancer	0.000859	0.00129	CcSEcCtD
Nafarelin—Anorexia—Irinotecan—pancreatic cancer	0.000855	0.00129	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PPY—pancreatic cancer	0.000854	0.00291	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Gemcitabine—pancreatic cancer	0.000844	0.00127	CcSEcCtD
Nafarelin—Hot flush—Doxorubicin—pancreatic cancer	0.000841	0.00127	CcSEcCtD
Nafarelin—Dizziness—Tamoxifen—pancreatic cancer	0.000841	0.00127	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—SSTR2—pancreatic cancer	0.000838	0.00286	CbGpPWpGaD
Nafarelin—Increased appetite—Doxorubicin—pancreatic cancer	0.000838	0.00126	CcSEcCtD
Nafarelin—Affect lability—Epirubicin—pancreatic cancer	0.000837	0.00126	CcSEcCtD
Nafarelin—Menopausal symptoms—Doxorubicin—pancreatic cancer	0.000834	0.00126	CcSEcCtD
Nafarelin—Anorexia—Gemcitabine—pancreatic cancer	0.000833	0.00125	CcSEcCtD
Nafarelin—Dizziness—Erlotinib—pancreatic cancer	0.000832	0.00125	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CNR1—pancreatic cancer	0.000821	0.0028	CbGpPWpGaD
Nafarelin—Anorexia—Fluorouracil—pancreatic cancer	0.000819	0.00123	CcSEcCtD
Nafarelin—Insomnia—Irinotecan—pancreatic cancer	0.000811	0.00122	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CCKBR—pancreatic cancer	0.00081	0.00276	CbGpPWpGaD
Nafarelin—Vomiting—Tamoxifen—pancreatic cancer	0.000808	0.00122	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—SST—pancreatic cancer	0.000808	0.00276	CbGpPWpGaD
Nafarelin—Mood swings—Epirubicin—pancreatic cancer	0.000806	0.00121	CcSEcCtD
Nafarelin—GNRHR—Class A/1 (Rhodopsin-like receptors)—CXCL8—pancreatic cancer	0.000805	0.00275	CbGpPWpGaD
Nafarelin—Paraesthesia—Irinotecan—pancreatic cancer	0.000805	0.00121	CcSEcCtD
Nafarelin—Cerebrovascular accident—Doxorubicin—pancreatic cancer	0.000803	0.00121	CcSEcCtD
Nafarelin—Rash—Tamoxifen—pancreatic cancer	0.000801	0.00121	CcSEcCtD
Nafarelin—Dermatitis—Tamoxifen—pancreatic cancer	0.000801	0.00121	CcSEcCtD
Nafarelin—Vomiting—Erlotinib—pancreatic cancer	0.0008	0.00121	CcSEcCtD
Nafarelin—Dyspnoea—Irinotecan—pancreatic cancer	0.000799	0.0012	CcSEcCtD
Nafarelin—Headache—Tamoxifen—pancreatic cancer	0.000796	0.0012	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Gemcitabine—pancreatic cancer	0.000796	0.0012	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—pancreatic cancer	0.000795	0.00271	CbGpPWpGaD
Nafarelin—Rash—Erlotinib—pancreatic cancer	0.000793	0.00119	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—GCG—pancreatic cancer	0.000793	0.00271	CbGpPWpGaD
Nafarelin—Dermatitis—Erlotinib—pancreatic cancer	0.000792	0.00119	CcSEcCtD
Nafarelin—Insomnia—Gemcitabine—pancreatic cancer	0.00079	0.00119	CcSEcCtD
Nafarelin—Headache—Erlotinib—pancreatic cancer	0.000788	0.00119	CcSEcCtD
Nafarelin—Paraesthesia—Gemcitabine—pancreatic cancer	0.000784	0.00118	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Fluorouracil—pancreatic cancer	0.000782	0.00118	CcSEcCtD
Nafarelin—Asthenia—Sunitinib—pancreatic cancer	0.000781	0.00118	CcSEcCtD
Nafarelin—Dry skin—Epirubicin—pancreatic cancer	0.00078	0.00118	CcSEcCtD
Nafarelin—Decreased appetite—Irinotecan—pancreatic cancer	0.00078	0.00117	CcSEcCtD
Nafarelin—Dyspnoea—Gemcitabine—pancreatic cancer	0.000779	0.00117	CcSEcCtD
Nafarelin—Insomnia—Fluorouracil—pancreatic cancer	0.000777	0.00117	CcSEcCtD
Nafarelin—Affect lability—Doxorubicin—pancreatic cancer	0.000775	0.00117	CcSEcCtD
Nafarelin—GNRHR—G alpha (q) signalling events—PIK3CA—pancreatic cancer	0.000771	0.00263	CbGpPWpGaD
Nafarelin—Paraesthesia—Fluorouracil—pancreatic cancer	0.000771	0.00116	CcSEcCtD
Nafarelin—Alopecia—Docetaxel—pancreatic cancer	0.000771	0.00116	CcSEcCtD
Nafarelin—Pruritus—Sunitinib—pancreatic cancer	0.00077	0.00116	CcSEcCtD
Nafarelin—Constipation—Irinotecan—pancreatic cancer	0.000767	0.00116	CcSEcCtD
Nafarelin—Dyspnoea—Fluorouracil—pancreatic cancer	0.000766	0.00115	CcSEcCtD
Nafarelin—Mental disorder—Docetaxel—pancreatic cancer	0.000764	0.00115	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GLI1—pancreatic cancer	0.000761	0.0026	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—DTX4—pancreatic cancer	0.000761	0.0026	CbGpPWpGaD
Nafarelin—Malnutrition—Docetaxel—pancreatic cancer	0.00076	0.00114	CcSEcCtD
Nafarelin—Decreased appetite—Gemcitabine—pancreatic cancer	0.000759	0.00114	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—AGTR1—pancreatic cancer	0.000756	0.00258	CbGpPWpGaD
Nafarelin—Nausea—Tamoxifen—pancreatic cancer	0.000755	0.00114	CcSEcCtD
Nafarelin—Gastritis—Epirubicin—pancreatic cancer	0.000753	0.00113	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—pancreatic cancer	0.000751	0.00256	CbGpPWpGaD
Nafarelin—Muscular weakness—Epirubicin—pancreatic cancer	0.00075	0.00113	CcSEcCtD
Nafarelin—Constipation—Gemcitabine—pancreatic cancer	0.000747	0.00113	CcSEcCtD
Nafarelin—Nausea—Erlotinib—pancreatic cancer	0.000747	0.00113	CcSEcCtD
Nafarelin—Decreased appetite—Fluorouracil—pancreatic cancer	0.000747	0.00113	CcSEcCtD
Nafarelin—Mood swings—Doxorubicin—pancreatic cancer	0.000746	0.00112	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—CNR1—pancreatic cancer	0.000746	0.00254	CbGpPWpGaD
Nafarelin—Diarrhoea—Sunitinib—pancreatic cancer	0.000745	0.00112	CcSEcCtD
Nafarelin—Dysgeusia—Docetaxel—pancreatic cancer	0.000744	0.00112	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—NRP1—pancreatic cancer	0.000741	0.00253	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PPP2R5B—pancreatic cancer	0.000741	0.00253	CbGpPWpGaD
Nafarelin—Abdominal distension—Epirubicin—pancreatic cancer	0.00074	0.00112	CcSEcCtD
Nafarelin—Dry skin—Doxorubicin—pancreatic cancer	0.000722	0.00109	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—GCG—pancreatic cancer	0.00072	0.00246	CbGpPWpGaD
Nafarelin—Dizziness—Sunitinib—pancreatic cancer	0.00072	0.00108	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—HEY2—pancreatic cancer	0.000713	0.00243	CbGpPWpGaD
Nafarelin—Gastritis—Doxorubicin—pancreatic cancer	0.000697	0.00105	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GAST—pancreatic cancer	0.000696	0.00238	CbGpPWpGaD
Nafarelin—Muscular weakness—Doxorubicin—pancreatic cancer	0.000694	0.00105	CcSEcCtD
Nafarelin—Vomiting—Sunitinib—pancreatic cancer	0.000692	0.00104	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—PIK3CA—pancreatic cancer	0.00069	0.00235	CbGpPWpGaD
Nafarelin—Dysuria—Epirubicin—pancreatic cancer	0.000688	0.00104	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—AGTR1—pancreatic cancer	0.000687	0.00234	CbGpPWpGaD
Nafarelin—Rash—Sunitinib—pancreatic cancer	0.000686	0.00103	CcSEcCtD
Nafarelin—Dermatitis—Sunitinib—pancreatic cancer	0.000686	0.00103	CcSEcCtD
Nafarelin—Abdominal distension—Doxorubicin—pancreatic cancer	0.000685	0.00103	CcSEcCtD
Nafarelin—Urticaria—Fluorouracil—pancreatic cancer	0.000682	0.00103	CcSEcCtD
Nafarelin—Headache—Sunitinib—pancreatic cancer	0.000682	0.00103	CcSEcCtD
Nafarelin—Palpitations—Docetaxel—pancreatic cancer	0.000671	0.00101	CcSEcCtD
Nafarelin—Weight increased—Epirubicin—pancreatic cancer	0.000669	0.00101	CcSEcCtD
Nafarelin—Weight decreased—Epirubicin—pancreatic cancer	0.000665	0.001	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—HEY1—pancreatic cancer	0.00066	0.00225	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SCT—pancreatic cancer	0.00066	0.00225	CbGpPWpGaD
Nafarelin—Convulsion—Docetaxel—pancreatic cancer	0.000658	0.000992	CcSEcCtD
Nafarelin—Chest pain—Docetaxel—pancreatic cancer	0.000647	0.000975	CcSEcCtD
Nafarelin—Arthralgia—Docetaxel—pancreatic cancer	0.000647	0.000975	CcSEcCtD
Nafarelin—Myalgia—Docetaxel—pancreatic cancer	0.000647	0.000975	CcSEcCtD
Nafarelin—Nausea—Sunitinib—pancreatic cancer	0.000647	0.000975	CcSEcCtD
Nafarelin—Asthenia—Irinotecan—pancreatic cancer	0.000643	0.00097	CcSEcCtD
Nafarelin—GNRHR—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—pancreatic cancer	0.000638	0.00218	CbGpPWpGaD
Nafarelin—Conjunctivitis—Epirubicin—pancreatic cancer	0.000637	0.00096	CcSEcCtD
Nafarelin—Dysuria—Doxorubicin—pancreatic cancer	0.000636	0.000959	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CCK—pancreatic cancer	0.00063	0.00215	CbGpPWpGaD
Nafarelin—Asthenia—Gemcitabine—pancreatic cancer	0.000627	0.000945	CcSEcCtD
Nafarelin—Oedema—Docetaxel—pancreatic cancer	0.00062	0.000934	CcSEcCtD
Nafarelin—Weight increased—Doxorubicin—pancreatic cancer	0.000619	0.000933	CcSEcCtD
Nafarelin—Epistaxis—Epirubicin—pancreatic cancer	0.000618	0.000932	CcSEcCtD
Nafarelin—Pruritus—Gemcitabine—pancreatic cancer	0.000618	0.000931	CcSEcCtD
Nafarelin—Weight decreased—Doxorubicin—pancreatic cancer	0.000616	0.000928	CcSEcCtD
Nafarelin—Sinusitis—Epirubicin—pancreatic cancer	0.000615	0.000927	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GLP1R—pancreatic cancer	0.000614	0.00209	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CNR2—pancreatic cancer	0.000614	0.00209	CbGpPWpGaD
Nafarelin—Diarrhoea—Irinotecan—pancreatic cancer	0.000614	0.000925	CcSEcCtD
Nafarelin—GNRHR—GPCR ligand binding—CXCL8—pancreatic cancer	0.000613	0.00209	CbGpPWpGaD
Nafarelin—Shock—Docetaxel—pancreatic cancer	0.00061	0.000919	CcSEcCtD
Nafarelin—Pruritus—Fluorouracil—pancreatic cancer	0.000608	0.000916	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CCKAR—pancreatic cancer	0.000604	0.00206	CbGpPWpGaD
Nafarelin—Diarrhoea—Gemcitabine—pancreatic cancer	0.000598	0.000901	CcSEcCtD
Nafarelin—Dizziness—Irinotecan—pancreatic cancer	0.000593	0.000894	CcSEcCtD
Nafarelin—Anorexia—Docetaxel—pancreatic cancer	0.000591	0.000891	CcSEcCtD
Nafarelin—Rhinitis—Epirubicin—pancreatic cancer	0.00059	0.000889	CcSEcCtD
Nafarelin—Conjunctivitis—Doxorubicin—pancreatic cancer	0.00059	0.000889	CcSEcCtD
Nafarelin—Diarrhoea—Fluorouracil—pancreatic cancer	0.000588	0.000886	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—JAG2—pancreatic cancer	0.000585	0.002	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MEN1—pancreatic cancer	0.000577	0.00197	CbGpPWpGaD
Nafarelin—Epistaxis—Doxorubicin—pancreatic cancer	0.000572	0.000862	CcSEcCtD
Nafarelin—Vomiting—Irinotecan—pancreatic cancer	0.00057	0.000859	CcSEcCtD
Nafarelin—Sinusitis—Doxorubicin—pancreatic cancer	0.000569	0.000858	CcSEcCtD
Nafarelin—Dizziness—Fluorouracil—pancreatic cancer	0.000568	0.000856	CcSEcCtD
Nafarelin—Rash—Irinotecan—pancreatic cancer	0.000565	0.000852	CcSEcCtD
Nafarelin—Dermatitis—Irinotecan—pancreatic cancer	0.000565	0.000851	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Docetaxel—pancreatic cancer	0.000565	0.000851	CcSEcCtD
Nafarelin—Headache—Irinotecan—pancreatic cancer	0.000562	0.000847	CcSEcCtD
Nafarelin—Insomnia—Docetaxel—pancreatic cancer	0.000561	0.000845	CcSEcCtD
Nafarelin—Paraesthesia—Docetaxel—pancreatic cancer	0.000557	0.000839	CcSEcCtD
Nafarelin—Vomiting—Gemcitabine—pancreatic cancer	0.000555	0.000837	CcSEcCtD
Nafarelin—Dyspnoea—Docetaxel—pancreatic cancer	0.000553	0.000833	CcSEcCtD
Nafarelin—Rash—Gemcitabine—pancreatic cancer	0.000551	0.00083	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—SHH—pancreatic cancer	0.00055	0.00188	CbGpPWpGaD
Nafarelin—Dermatitis—Gemcitabine—pancreatic cancer	0.00055	0.000829	CcSEcCtD
Nafarelin—Headache—Gemcitabine—pancreatic cancer	0.000547	0.000825	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—NOTCH4—pancreatic cancer	0.000547	0.00187	CbGpPWpGaD
Nafarelin—Vomiting—Fluorouracil—pancreatic cancer	0.000546	0.000823	CcSEcCtD
Nafarelin—Rhinitis—Doxorubicin—pancreatic cancer	0.000546	0.000823	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—IAPP—pancreatic cancer	0.000544	0.00185	CbGpPWpGaD
Nafarelin—Rash—Fluorouracil—pancreatic cancer	0.000542	0.000816	CcSEcCtD
Nafarelin—Dermatitis—Fluorouracil—pancreatic cancer	0.000541	0.000815	CcSEcCtD
Nafarelin—Decreased appetite—Docetaxel—pancreatic cancer	0.000539	0.000812	CcSEcCtD
Nafarelin—Headache—Fluorouracil—pancreatic cancer	0.000538	0.000811	CcSEcCtD
Nafarelin—Desmopressin—PTGS2—pancreatic cancer	0.000533	0.0123	CrCbGaD
Nafarelin—Nausea—Irinotecan—pancreatic cancer	0.000533	0.000803	CcSEcCtD
Nafarelin—Constipation—Docetaxel—pancreatic cancer	0.00053	0.000799	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PTHLH—pancreatic cancer	0.000522	0.00178	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTCH1—pancreatic cancer	0.000522	0.00178	CbGpPWpGaD
Nafarelin—Alopecia—Epirubicin—pancreatic cancer	0.00052	0.000784	CcSEcCtD
Nafarelin—Nausea—Gemcitabine—pancreatic cancer	0.000519	0.000782	CcSEcCtD
Nafarelin—Mental disorder—Epirubicin—pancreatic cancer	0.000516	0.000777	CcSEcCtD
Nafarelin—Malnutrition—Epirubicin—pancreatic cancer	0.000512	0.000772	CcSEcCtD
Nafarelin—Nausea—Fluorouracil—pancreatic cancer	0.00051	0.000769	CcSEcCtD
Nafarelin—Tension—Epirubicin—pancreatic cancer	0.000503	0.000758	CcSEcCtD
Nafarelin—Dysgeusia—Epirubicin—pancreatic cancer	0.000502	0.000756	CcSEcCtD
Nafarelin—Nervousness—Epirubicin—pancreatic cancer	0.000498	0.00075	CcSEcCtD
Nafarelin—Alopecia—Doxorubicin—pancreatic cancer	0.000481	0.000725	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—SST—pancreatic cancer	0.000477	0.00163	CbGpPWpGaD
Nafarelin—Mental disorder—Doxorubicin—pancreatic cancer	0.000477	0.000719	CcSEcCtD
Nafarelin—Malnutrition—Doxorubicin—pancreatic cancer	0.000474	0.000714	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CG—pancreatic cancer	0.000471	0.00161	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—JAG1—pancreatic cancer	0.000467	0.00159	CbGpPWpGaD
Nafarelin—Tension—Doxorubicin—pancreatic cancer	0.000465	0.000701	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—NOTCH3—pancreatic cancer	0.000465	0.00159	CbGpPWpGaD
Nafarelin—Dysgeusia—Doxorubicin—pancreatic cancer	0.000464	0.0007	CcSEcCtD
Nafarelin—Nervousness—Doxorubicin—pancreatic cancer	0.00046	0.000694	CcSEcCtD
Nafarelin—Vertigo—Epirubicin—pancreatic cancer	0.00046	0.000694	CcSEcCtD
Nafarelin—Palpitations—Epirubicin—pancreatic cancer	0.000453	0.000682	CcSEcCtD
Nafarelin—Asthenia—Docetaxel—pancreatic cancer	0.000445	0.00067	CcSEcCtD
Nafarelin—Convulsion—Epirubicin—pancreatic cancer	0.000444	0.000669	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—CNR1—pancreatic cancer	0.00044	0.0015	CbGpPWpGaD
Nafarelin—Pruritus—Docetaxel—pancreatic cancer	0.000439	0.000661	CcSEcCtD
Nafarelin—Chest pain—Epirubicin—pancreatic cancer	0.000436	0.000657	CcSEcCtD
Nafarelin—Arthralgia—Epirubicin—pancreatic cancer	0.000436	0.000657	CcSEcCtD
Nafarelin—Myalgia—Epirubicin—pancreatic cancer	0.000436	0.000657	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CG—pancreatic cancer	0.000427	0.00146	CbGpPWpGaD
Nafarelin—Vertigo—Doxorubicin—pancreatic cancer	0.000426	0.000642	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—GCG—pancreatic cancer	0.000425	0.00145	CbGpPWpGaD
Nafarelin—Diarrhoea—Docetaxel—pancreatic cancer	0.000424	0.000639	CcSEcCtD
Nafarelin—Palpitations—Doxorubicin—pancreatic cancer	0.000419	0.000631	CcSEcCtD
Nafarelin—Oedema—Epirubicin—pancreatic cancer	0.000418	0.00063	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CD—pancreatic cancer	0.000414	0.00141	CbGpPWpGaD
Nafarelin—Shock—Epirubicin—pancreatic cancer	0.000411	0.00062	CcSEcCtD
Nafarelin—Convulsion—Doxorubicin—pancreatic cancer	0.000411	0.000619	CcSEcCtD
Nafarelin—Dizziness—Docetaxel—pancreatic cancer	0.00041	0.000618	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—AGTR1—pancreatic cancer	0.000406	0.00138	CbGpPWpGaD
Nafarelin—Hyperhidrosis—Epirubicin—pancreatic cancer	0.000404	0.000609	CcSEcCtD
Nafarelin—Arthralgia—Doxorubicin—pancreatic cancer	0.000404	0.000608	CcSEcCtD
Nafarelin—Chest pain—Doxorubicin—pancreatic cancer	0.000404	0.000608	CcSEcCtD
Nafarelin—Myalgia—Doxorubicin—pancreatic cancer	0.000404	0.000608	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—STK11—pancreatic cancer	0.0004	0.00136	CbGpPWpGaD
Nafarelin—Anorexia—Epirubicin—pancreatic cancer	0.000399	0.000601	CcSEcCtD
Nafarelin—Vomiting—Docetaxel—pancreatic cancer	0.000394	0.000594	CcSEcCtD
Nafarelin—Rash—Docetaxel—pancreatic cancer	0.000391	0.000589	CcSEcCtD
Nafarelin—Dermatitis—Docetaxel—pancreatic cancer	0.00039	0.000588	CcSEcCtD
Nafarelin—Headache—Docetaxel—pancreatic cancer	0.000388	0.000585	CcSEcCtD
Nafarelin—Oedema—Doxorubicin—pancreatic cancer	0.000387	0.000583	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Epirubicin—pancreatic cancer	0.000381	0.000574	CcSEcCtD
Nafarelin—Shock—Doxorubicin—pancreatic cancer	0.000381	0.000574	CcSEcCtD
Nafarelin—Insomnia—Epirubicin—pancreatic cancer	0.000378	0.00057	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CD—pancreatic cancer	0.000376	0.00128	CbGpPWpGaD
Nafarelin—Paraesthesia—Epirubicin—pancreatic cancer	0.000375	0.000566	CcSEcCtD
Nafarelin—Hyperhidrosis—Doxorubicin—pancreatic cancer	0.000374	0.000564	CcSEcCtD
Nafarelin—Dyspnoea—Epirubicin—pancreatic cancer	0.000373	0.000562	CcSEcCtD
Nafarelin—Anorexia—Doxorubicin—pancreatic cancer	0.000369	0.000556	CcSEcCtD
Nafarelin—Nausea—Docetaxel—pancreatic cancer	0.000368	0.000555	CcSEcCtD
Nafarelin—Decreased appetite—Epirubicin—pancreatic cancer	0.000363	0.000548	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CB—pancreatic cancer	0.000361	0.00123	CbGpPWpGaD
Nafarelin—Constipation—Epirubicin—pancreatic cancer	0.000358	0.000539	CcSEcCtD
Nafarelin—Musculoskeletal discomfort—Doxorubicin—pancreatic cancer	0.000352	0.000531	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—SMAD4—pancreatic cancer	0.00035	0.0012	CbGpPWpGaD
Nafarelin—Insomnia—Doxorubicin—pancreatic cancer	0.00035	0.000527	CcSEcCtD
Nafarelin—Paraesthesia—Doxorubicin—pancreatic cancer	0.000347	0.000524	CcSEcCtD
Nafarelin—GNRHR—GPCR downstream signaling—CXCL8—pancreatic cancer	0.000347	0.00118	CbGpPWpGaD
Nafarelin—Dyspnoea—Doxorubicin—pancreatic cancer	0.000345	0.00052	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—HES1—pancreatic cancer	0.000342	0.00117	CbGpPWpGaD
Nafarelin—Decreased appetite—Doxorubicin—pancreatic cancer	0.000336	0.000507	CcSEcCtD
Nafarelin—Urticaria—Epirubicin—pancreatic cancer	0.000332	0.000501	CcSEcCtD
Nafarelin—Constipation—Doxorubicin—pancreatic cancer	0.000331	0.000499	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CB—pancreatic cancer	0.000328	0.00112	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—CXCL8—pancreatic cancer	0.000315	0.00107	CbGpPWpGaD
Nafarelin—Urticaria—Doxorubicin—pancreatic cancer	0.000307	0.000463	CcSEcCtD
Nafarelin—Asthenia—Epirubicin—pancreatic cancer	0.0003	0.000452	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—TERT—pancreatic cancer	0.0003	0.00102	CbGpPWpGaD
Nafarelin—Pruritus—Epirubicin—pancreatic cancer	0.000296	0.000446	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—HIF1A—pancreatic cancer	0.000287	0.000978	CbGpPWpGaD
Nafarelin—Diarrhoea—Epirubicin—pancreatic cancer	0.000286	0.000431	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—TSC2—pancreatic cancer	0.000286	0.000975	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—APOE—pancreatic cancer	0.00028	0.000955	CbGpPWpGaD
Nafarelin—Asthenia—Doxorubicin—pancreatic cancer	0.000278	0.000418	CcSEcCtD
Nafarelin—Dizziness—Epirubicin—pancreatic cancer	0.000276	0.000417	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—KDR—pancreatic cancer	0.000274	0.000935	CbGpPWpGaD
Nafarelin—Pruritus—Doxorubicin—pancreatic cancer	0.000274	0.000412	CcSEcCtD
Nafarelin—Vomiting—Epirubicin—pancreatic cancer	0.000266	0.000401	CcSEcCtD
Nafarelin—Diarrhoea—Doxorubicin—pancreatic cancer	0.000265	0.000399	CcSEcCtD
Nafarelin—Rash—Epirubicin—pancreatic cancer	0.000264	0.000397	CcSEcCtD
Nafarelin—Dermatitis—Epirubicin—pancreatic cancer	0.000263	0.000397	CcSEcCtD
Nafarelin—Headache—Epirubicin—pancreatic cancer	0.000262	0.000395	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—NFKBIA—pancreatic cancer	0.000261	0.000889	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NOTCH1—pancreatic cancer	0.000258	0.000881	CbGpPWpGaD
Nafarelin—Dizziness—Doxorubicin—pancreatic cancer	0.000256	0.000386	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PIK3CG—pancreatic cancer	0.000252	0.000861	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—NRAS—pancreatic cancer	0.000252	0.000861	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EGF—pancreatic cancer	0.00025	0.000852	CbGpPWpGaD
Nafarelin—Nausea—Epirubicin—pancreatic cancer	0.000248	0.000374	CcSEcCtD
Nafarelin—Vomiting—Doxorubicin—pancreatic cancer	0.000246	0.000371	CcSEcCtD
Nafarelin—Rash—Doxorubicin—pancreatic cancer	0.000244	0.000368	CcSEcCtD
Nafarelin—Dermatitis—Doxorubicin—pancreatic cancer	0.000244	0.000367	CcSEcCtD
Nafarelin—Headache—Doxorubicin—pancreatic cancer	0.000242	0.000365	CcSEcCtD
Nafarelin—GNRHR—Signaling by GPCR—EGFR—pancreatic cancer	0.00023	0.000785	CbGpPWpGaD
Nafarelin—Nausea—Doxorubicin—pancreatic cancer	0.00023	0.000346	CcSEcCtD
Nafarelin—GNRHR—Signaling Pathways—PIK3CD—pancreatic cancer	0.000222	0.000757	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—PIK3CA—pancreatic cancer	0.00022	0.00075	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—KRAS—pancreatic cancer	0.000217	0.000741	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—PIK3CA—pancreatic cancer	0.0002	0.000681	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CB—pancreatic cancer	0.000193	0.00066	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CXCL8—pancreatic cancer	0.000186	0.000634	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—HRAS—pancreatic cancer	0.000185	0.00063	CbGpPWpGaD
Nafarelin—GNRHR—GPCR downstream signaling—AKT1—pancreatic cancer	0.00018	0.000613	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CASP3—pancreatic cancer	0.000178	0.000607	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CCND1—pancreatic cancer	0.000173	0.000591	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—CTNNB1—pancreatic cancer	0.000172	0.000585	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MMP9—pancreatic cancer	0.000168	0.000574	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PTEN—pancreatic cancer	0.000167	0.00057	CbGpPWpGaD
Nafarelin—GNRHR—Signaling by GPCR—AKT1—pancreatic cancer	0.000163	0.000556	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—SRC—pancreatic cancer	0.000155	0.000529	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—VEGFA—pancreatic cancer	0.000151	0.000515	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—STAT3—pancreatic cancer	0.00015	0.00051	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—NRAS—pancreatic cancer	0.000149	0.000509	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—MYC—pancreatic cancer	0.000139	0.000474	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TGFB1—pancreatic cancer	0.000139	0.000473	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—EGFR—pancreatic cancer	0.000136	0.000464	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—KRAS—pancreatic cancer	0.000128	0.000438	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—PIK3CA—pancreatic cancer	0.000118	0.000402	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—TP53—pancreatic cancer	0.000114	0.000389	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—HRAS—pancreatic cancer	0.000109	0.000372	CbGpPWpGaD
Nafarelin—GNRHR—Signaling Pathways—AKT1—pancreatic cancer	9.63e-05	0.000329	CbGpPWpGaD
